Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-PALISADE
2025-522954-37-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial of REGN7508 and amrecibart in arteriosclerosis obliterans (4 arms), sponsored by Regeneron Pharmaceuticals. Planned start Sep 2026; status: authorised.
02
Drugs
REGN7508amrecibart
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on 2025-522954-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522954-37-00.